Total Body Albumin Measurement Utilizing a Modification of the BVA 100 Blood Volume Analyzer
Information source: Daxor Corporation
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypoalbuminemia; Heart Failure; Nephrosis; Cirrhosis; Shock
Phase: N/A
Status: Completed
Sponsored by: Daxor Corporation Official(s) and/or principal investigator(s):
Joseph Feldschuh, MD, Principal Investigator, Affiliation: Daxor Corporation
Summary
The DAXOR Corporation manufactures and distributes a blood volume analyzer. The analysis is
based on the tracer dilution principle utilizing radioiodine labeled human serum albumin. In
addition to calculating human blood volume it is hypothesized that measurement of the
dilution of the tracer can also yield an accurate measurement of total body albumin.
Clinical Details
Official title: Pilot Research Study to Asses Total Body Albumin Levels
Study design: Observational Model: Cohort, Time Perspective: Prospective
Primary outcome: Total Body Albumin
Detailed description:
Twenty adult individuals underwent a standard blood volume measurement. The specimens for
this determination are normally collected over a period of approximately 40 minutes. For the
determination of total body albumin, additional specimens were collect over a three to four
day period until the counts in the blood specimens were stable. Calculation of the degree of
dilution over this time interval is thought to represent dilution of the tracer in albumin
in both the intra and extravascular space. The ratio of albumin in the intravascular to the
extravascular space is available in the medical literature. The total volume in which the
tracer is distributed can be determined from the dilution determined. A calculation of total
body albumin is therefore possible. Computation of the total body albumin for the test
subjects (all normal individuals) was consistent with values for total body albumin in the
literature. The purpose of the development of this method is to permit clinicians to
determine albumin status in patients with disturbances in albumin such as burn patients,
cirrhotic patients, nephrotic patients as well as patients with protein losing
gastroenteropathies.
Eligibility
Minimum age: 18 Years.
Maximum age: 80 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Normal adult males and females.
- Females in the childbearing age group to have test to exclude pregnancy
Exclusion Criteria:
- Children,
- pregnant females
Locations and Contacts
Additional Information
Starting date: January 2009
Last updated: March 1, 2012
|
